Overview of Chemotherapy Devices MarketThe Global Chemotherapy Devices Market is valued at USD 0.21 Billion in 2024 and is ...

DSCI has been designated the nodal training centre under the Prime Minister's DCCC initiative. "This initiative aims to ...

An Alabama woman drove to Tampa for answers about her late father’s missing money. Money that she said was siphoned by ...

US-based PanTher Therapeutics has initiated a trial of its chemotherapy-eluting patch, which it hopes will make cancer ...

A panelist discusses how given PODIUM-303's benefits across all subgroups, the primary patient population that should receive chemotherapy alone rather than the combination with retifanlimab would be ...

A Pinellas County businessman accused of orchestrating a massive fraud scheme appeared in federal court on Thursday afternoon ...

Monjuvi added to Rituxan and Revlimid extended progression-free survival from 14 to 22 months in follicular lymphoma, ...

The Trump administration wants to boost Medicare payments for hospital outpatient services by $8.1 billion next year — while ...

Cancer patients who receive COVID boosters are far less likely to be hospitalized, but vaccination rates remain alarmingly ...

The FDA has accepted the supplemental new drug application for decitabine/cedazuridine plus venetoclax to treat adults with AML.

The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for decitabine/cedazuridine plus venetoclax to treat adults with newly diagnosed acute myeloid leukemia ...

I N 1971 RICHARD NIXON, then America’s president, announced a “war on cancer”. Just two years earlier the Apollo programme ...